AMS

Business Context and Reporting Period

Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: ASHS provides radiation therapy equipment and services, primarily through Gamma Knife units. As of June 30, 2010, the company operated 19 Gamma Knife units across 19 medical centers. The company also holds a significant investment in Still River Systems, Inc., a developer of proton beam radiation therapy (PBRT) systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Medical services revenue decreased by 9.3% ($428,000) for the quarter and 5.8% ($507,000) for the six-month period compared to 2009. This was primarily driven by a shift in Gamma Knife procedure volume to sites with lower payment rates, despite a slight increase in total procedures for the six-month period.
• Cost Reductions: Total costs of revenue decreased by 9.8% for the quarter and 8.4% for the six-month period. Depreciation and amortization expenses dropped significantly due to extended asset lives on certain units and some equipment reaching salvage value.
• Transaction Costs: Transaction costs were $0 in 2010, compared to $123,000 (quarter) and $320,000 (six months) in 2009, which were related to terminated negotiations for the sale of a subsidiary interest.
• Profitability: While consolidated net income increased, net income attributable to ASHS shareholders remained minimal ($3,000 for the quarter, $11,000 for six months) due to the significant portion of income allocated to non-controlling interests (19% stake in GK Financing).

Outlook, Risks, and Management Commentary

• Liquidity: Cash and cash equivalents decreased to $527,000. The company maintains a $9,000,000 line of credit, of which $8,500,000 was drawn as of June 30, 2010. Management believes cash flow from operations is adequate to meet scheduled debt obligations for the next 12 months.
• Capital Commitments: The company has approximately $43,000,000 in remaining commitments to purchase equipment, including three Monarch250 proton beam systems from Still River and additional Gamma Knife units. Financing for these projects is contingent on market conditions and FDA approval for the Still River systems.
• Still River Investment Risk: ASHS holds a $2,617,000 investment in Still River Systems. Management notes an unrealized loss of approximately $1.2 million based on recent financing rounds but classifies the impairment as "temporary," citing Still River's ability to raise capital and progress toward FDA approval.
• Operational Risks: Risks include the development stage nature of the Still River PBRT technology, potential delays in FDA approval, and the difficulty of obtaining financing in the current credit market environment.

Key Facts for Investor Verification

• Debt Servicing: Verify the company's ability to service approximately $4,963,000 in debt and $3,720,000 in capital lease payments due within the next 12 months given the high utilization of its line of credit.
• Still River Viability: Monitor the progress of Still River Systems toward FDA approval for the Monarch250 system, as this is critical for the realization of ASHS's $43 million in equipment commitments and the recovery of its investment value.
• Revenue Mix: Assess the long-term impact of the shift in Gamma Knife volume toward lower-paying sites on future gross margins.
• Non-Controlling Interest: Note that the majority of consolidated net income is attributable to non-controlling interests; verify the specific profitability drivers of the GK Financing subsidiary.